Author of the publication

copy delete add this publication to your clipboard
community post
history of this post
URL
DOI
BibTeX
EndNote
APA
Chicago
DIN 1505
Harvard
MSOffice XML

The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis

M. Rehak, J. Rehak, M. Müller, S. Faude, F. Faude, A. Siegemund, V. Krcova, L. Slavik, D. Hasenclever, M. Scholz, and P. Wiedemann. Thrombosis and haemostasis, 99 (5): 925–929 (2008)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Dirk Hasenclever

Hertha Hasenclever

Max Hasenclever

Christa Hasenclever

Jörg Hasenclever

Other publications of authors with the same name

Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 studyC. Mauz-Körholz, D. Hasenclever, W. Dörffel, K. Ruschke, T. Pelz, A. Voigt, M. Stiefel, M. Winkler, C. Vilser, K. Dieckmann and 10 other author(s). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (23): 3680–3686 (2010)The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysisM. Rehak, J. Rehak, M. Müller, S. Faude, F. Faude, A. Siegemund, V. Krcova, L. Slavik, D. Hasenclever, M. Scholz and 1 other author(s). Thrombosis and haemostasis, 99 (5): 925–929 (2008)Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLM. Pfreundschuh, L. Trümper, M. Kloess, R. Schmits, A. Feller, C. Rübe, C. Rudolph, M. Reiser, D. Hossfeld, H. Eimermacher and 3 other author(s). Blood, 104 (3): 634–641 (2004)Development and implementation of an analysis tool for array-based comparative genomic hybridizationM. Kreuz, M. Rosolowski, H. Berger, C. Schwaenen, S. Wessendorf, M. Loeffler, and D. Hasenclever. Methods of information in medicine, 46 (5): 608–613 (2007)Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSFM. Pfreundschuh, D. Hasenclever, M. Loeffler, G. Ehninger, N. Schmitz, H. Kirchner, P. Koch, B. Lathan, U. Rueffer, M. Sextro and 3 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 12 (4): 471–477 (2001)Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidenceJ. Wiegand, D. Hasenclever, and H. Tillmann. Antiviral therapy, 13 (2): 211–220 (2008)Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study GroupM. Pfreundschuh, U. Rueffer, B. Lathan, N. Schmitz, O. Brosteanu, D. Hasenclever, R. Haas, H. Kirchner, P. Koch, and R. Kuse. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 (3): 580–586 (1994)The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studiesD. Körholz, A. Claviez, D. Hasenclever, R. Kluge, W. Hirsch, F. Kamprad, W. Dörffel, L. Wickmann, K. Papsdorf, K. Dieckmann and 7 other author(s). Klinische Pädiatrie, 216 (3): 150–156 (2004)Are endoscopic antireflux therapies cost-effective compared with laparoscopic fundoplication?I. Schiefke, C. Rogalski, A. Zabel-Langhennig, H. Witzigmann, J. Mössner, D. Hasenclever, and K. Caca. Endoscopy, 37 (3): 217–222 (2005)High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML)T. Köhler, C. Schill, M. Deininger, R. Krahl, S. Borchert, D. Hasenclever, S. Leiblein, O. Wagner, and D. Niederwieser. Leukemia, 16 (1): 22–29 (2002)

BibSonomy

Disambiguation of "Hasenclever, Dirk"